Bio-Rad Laboratories, Inc. · NYSE:BIO

Bio-Rad Laboratories — Jefferies 2019 Healthcare Conference

26 slides from Bio-Rad Laboratories's conference presentation, 2019

  1. Slide 1: Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference

    Slide 1: Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference

    Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our investment in high growth emerging markets and development of new prod

  3. Slide 3: Bio-Rad Today

    Slide 3: Bio-Rad Today

    Bio-Rad Today Continuous 65+ Years Strong Innovation A History of Contribution Performance Key Competencies $2.2B+ Annual Sales Fueling Ongoing Growth Complementary 8,300+ Employees Worldwide Business Mix Leveraging Across the Company Advance discovery. Improve lives.

  4. Slide 4: Bio-Rad Global Profile

    Slide 4: Bio-Rad Global Profile

    Bio-Rad Global Profile Applied 3% BioPharma Asia 11% EMEA 21% Hospital Labs 35% 38% Academic 23% Customers Geography Products Transfusion Labs Reference Labs Americas 13% 12% 44% Diversified Customer Base Worldwide Presence Broad Product Base Advance discovery. Improve lives.

  5. Slide 5: A History of Innovation

    Slide 5: A History of Innovation

    A History of Innovation 2012 1982: First commercial Bio-Rad launches the 1967: Bio-Rad launches first T-4 test for Hemoglobin A1c droplet digital PCR by column test revolutionizing system Thyroid testing 2006: Place first multiplex immunoassay system BioPlex 2200 2000 Launched the first 4- color rea

  6. Slide 6: Leadership Positions

    Slide 6: Leadership Positions

    Leadership Positions DNA amplification Autoimmune Bio-Chromatography Diabetes Market Focus Infectious Disease Electrophoresis Blood Typing Gel image Quality Control Protein Assay Digital Biology Advance discovery. Improve lives.

  7. Slide 7: Bio-Rad is Well-Positioned in New Focus on Lab to Clinic Solutions

    Slide 7: Bio-Rad is Well-Positioned in New Focus on Lab to Clinic Solutions

    Bio-Rad is Well-Positioned in New Focus on Lab to Clinic Solutions Translational Research Continuum Discovery Development Production Treatment & follow up • Basic disease • Target validation • Clinical studies • Treatment mechanism • Lead development • Regulatory planning and research of a therapy a

  8. Slide 8: Life Science Profile

    Slide 8: Life Science Profile

    Life Science Profile Highlights  Market Size: $45B–50B  Market Growth 4% CAGR  Addressable Market: $8–9B Asia 26% Americas Research Applied Markets 43% Revenue Consumables 63% 7% Geography 48% Customer Products Segments EMEA BioPharma 31% Instruments/ Apparatus 30% 52% Source: Bio-Rad Internal 8

  9. Slide 9: Life Science Solutions

    Slide 9: Life Science Solutions

    Life Science Solutions Genotyping & Gene Gene Transfer & Modulation Protein Purification Expression (chromatography) (PCR & qPCR) Protein Expression (multi-analyte detection) Multi-omics Solutions Digital Biology (Droplet Digital PCR, ddSeq) Protein Quantification (western blotting) Cellular Imaging

  10. Slide 10: Cell Biology

    Slide 10: Cell Biology

    Cell Biology New Entrant in Growing Market  Flow Cytometry Cell Sorters and Analyzers Flow Cytometry  Cell Imagers and Counters Antibodies TC20 Automated  Flow Cytometry Reagents & Assays Cell Counter  Flow Cytometry Antibodies S3e Cell Sorter ZOE Fluorescent Cell Imager ZE5 Cell Analyzer 10 Adv

  11. Slide 11: Digital Biology

    Slide 11: Digital Biology

    Digital Biology Leadership Position • ddPCR technology • Broad IP portfolio • Broad application from research to therapeutics • Rapid development of new applications Advance discovery. Improve lives.

  12. Slide 12: Clinical Diagnostics Profile

    Slide 12: Clinical Diagnostics Profile

    Clinical Diagnostics Profile Highlights  Market Size: $55-60B Asia  Addressable Market: $5.5B 19%  Market Growth ~ 5% EMEA 39% Instruments Transfusion Revenue 25% Laboratory Geography 18% Customer Products Segments Hospital Americas Laboratory 42% Reference 61% Laboratory Reagents 21% 75% Source:

  13. Slide 13: Clinical Diagnostics

    Slide 13: Clinical Diagnostics

    Clinical Diagnostics Diagnostic Testing Protecting the Quality and Monitoring Blood Supply Assurance  Diabetes  Blood Typing  Quality Controls  Infectious Disease  Blood Virus Screening  Quality Assessments  Autoimmune  HIV Confirmation Testing  Data Management  Transfusion Compatibility 1

  14. Slide 14: Blood Typing

    Slide 14: Blood Typing

    Blood Typing Highlights  Bio-Rad #2 in Market  3,000+ Automated Systems Placed Gel Cards  Unrivalled Results Management  Broadest portfolio for safe transfusions Tango infinity Geographic Expansion  IH-1000 and IH-500 FDA Approvals  IH-Com and Manual Systems Approval  Growing Demand in Emergi

  15. Slide 15: Portfolio Expansion

    Slide 15: Portfolio Expansion

    Portfolio Expansion Near Term Focus • Core Market Enhancement • Microbiome • Point of Care • Non-Invasive Prenatal Testing Advance discovery. Improve lives.

  16. Slide 16: The Importance Of Clinical Diagnostics In Healthcare

    Slide 16: The Importance Of Clinical Diagnostics In Healthcare

    The Importance Of Clinical Diagnostics In Healthcare Targeted Disease Prevention Early Disease Detection Accelerated Diagnostics Targeted Therapy Earlier detection saves lives Improved • Lowers total costs Outcomes • Reduces risks • Increases satisfaction • Improves treatment efficiency 16 Advance d

  17. Slide 17: Diabetes

    Slide 17: Diabetes

    Diabetes Diabetes is an accelerating global problem. 17 Advance discovery. Improve lives.

  18. Slide 18: Bio-Rad Pioneered HbA1c Testing

    Slide 18: Bio-Rad Pioneered HbA1c Testing

    Bio-Rad Pioneered HbA1c Testing Bio-Rad provides HbA1c testing solutions for all segments, leading to better outcomes for patients with diabetes. Small Labs / Medium Labs Large Labs Clinics D-10 VARIANT II D-100 18 Advance discovery. Improve lives.

  19. Slide 19: Cancer

    Slide 19: Cancer

    Cancer The global cancer burden continues to rise, with 18 million new cases and over 9 million deaths in 2018. Early Detection Is Key To Survival 19 * Cancer Research UK Advance discovery. Improve lives.

  20. Slide 20: Bio-Rad Is Pioneering Digital PCR In Liquid Biopsy

    Slide 20: Bio-Rad Is Pioneering Digital PCR In Liquid Biopsy

    Bio-Rad Is Pioneering Digital PCR In Liquid Biopsy Bio-Rad products enable monitoring of a patient’s response to targeted therapy. Systems Consumables Menu Droplet digital PCR For customers developing Large portfolio of assays platforms and validating tests 20 Advance discovery. Improve lives.

  21. Slide 21: Translational Discovery to Diagnostics

    Slide 21: Translational Discovery to Diagnostics

    Translational Discovery to Diagnostics Discovery Production  Basic disease mechanism research  Clinical studies  Pathway research  Regulatory  Target identification Translational  Drug and/or diagnostics manufacturing and Medicine commercialization Development Therapies  Target validation  T

  22. Slide 22: Operational Transformation

    Slide 22: Operational Transformation

    Operational Transformation Building a Scalable Model Advance discovery. Improve lives.

  23. Slide 23: The Opportunity

    Slide 23: The Opportunity

    The Opportunity Leverage Rationalize Manage ERP Investment Global Footprint Procurement  Increase visibility  Consolidate distribution  Centralized Procurement centers  Global price concessions  Optimize inventory levels  Close redundant  Targeted reduction in  Improve service commercial sit

  24. Slide 24: The Path Forward

    Slide 24: The Path Forward

    The Path Forward  Geographic Expansion  Optimized Supply Chain  New Products  Reduced ERP Spend  New Markets Driving Expanding  Shared Services Revenue EBITDA  Operating Leverage Growth Margins  Increased Cash Flow Creating Accelerating  Higher Profitability Shareholder Free Cash  Discipli

  25. Slide 25: Summary – Closing Remarks

    Slide 25: Summary – Closing Remarks

    Summary – Closing Remarks  Investments at an inflection point  Building on our market and product leadership  Increased focus on acquisition opportunities  Leveraging our new organization, operating model and systems to drive value Advance discovery. Improve lives.

  26. Slide 26: Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference

    Slide 26: Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference

    Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference

Source: Internet Archive copy of bio-rad.com

More decks from Bio-Rad Laboratories, Inc.

All 24 Bio-Rad Laboratories decks